Intravitreal Ranibizumab versus Vitreous Lavage for Postoperative Vitreous Hemorrhage in Proliferative Diabetic Retinopathy: A Randomized Controlled Trial

Background: Postoperative vitreous hemorrhage (POVH) after pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR) is a common complication that delays visual recovery. While vitreous lavage (VL) mechanically clears hemorrhages, intravitreal ranibizumab (IVR) targets VEGF-mediated neovascularization. We compared the efficacy and safety of IVR and VL for the management of POVH. Objective: To compare the visual outcomes, hemorrhage clearance efficiency, and complications between IVR and VL over a 24-week follow-up period. Methods: ) quantified the recovery dynamics. Results: At 24 weeks, BCVA improvement was comparable between groups (VL: 0.30 LogMAR vs IVR: 0.22 LogMAR, p=0.47). VL achieved immediate BCVA gains in one day (1.99 vs 0.91 LogMAR, p